These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 1837113)

  • 1. [Acute clinical syndrome associated with OKT3 administration. Prevention by single injection of an anti-human TNF monoclonal antibody].
    Charpentier B; Hiesse C; Ferran C; Lantz O; Fries D; Bach JF; Chatenoud L
    Presse Med; 1991 Nov; 20(40):2009-11. PubMed ID: 1837113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence that antihuman tumor necrosis factor monoclonal antibody prevents OKT3-induced acute syndrome.
    Charpentier B; Hiesse C; Lantz O; Ferran C; Stephens S; O'Shaugnessy D; Bodmer M; Benoit G; Bach JF; Chatenoud L
    Transplantation; 1992 Dec; 54(6):997-1002. PubMed ID: 1465794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of recombinant human soluble dimeric tumor necrosis factor receptor for prevention of OKT3-associated acute clinical syndrome.
    Eason JD; Pascual M; Wee S; Farrell M; Phelan J; Boskovic S; Blosch C; Mohler KM; Cosimi AB
    Transplantation; 1996 Jan; 61(2):224-8. PubMed ID: 8600628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids.
    Chatenoud L; Ferran C; Legendre C; Thouard I; Merite S; Reuter A; Gevaert Y; Kreis H; Franchimont P; Bach JF
    Transplantation; 1990 Apr; 49(4):697-702. PubMed ID: 2109379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitization to OKT3 monoclonal antibody in heart transplantation: correlation with early allograft loss.
    O'Connell JB; Renlund DG; Hammond EH; Wittwer CT; Yowell RL; DeWitt CW; Jones KW; Gay WA; Menlove RL; Bristow MR
    J Heart Lung Transplant; 1991; 10(2):217-21; discussion 221-2. PubMed ID: 1903303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot trial of recombinant human interleukin-10 in kidney transplant recipients receiving OKT3 induction therapy.
    Wissing KM; Morelon E; Legendre C; De Pauw L; LeBeaut A; Grint P; Maniscalki M; Ickx B; Vereerstraeten P; Chatenoud L; Kreis H; Goldman M; Abramowicz D
    Transplantation; 1997 Oct; 64(7):999-1006. PubMed ID: 9381549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Reduction of TNF-alpha release and clinical effects of the first injection of OKT3].
    Meulders Q; Dallel T; Peraldi MN; Kanfer A; Sraer JD; Rondeau E
    Presse Med; 1992 Dec; 21(41):2024-6. PubMed ID: 1294974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo soluble tumor necrosis factor receptor release in OKT3-treated patients. Differential regulation of TNF-sR55 and TNF-sR75.
    Herbelin A; Chatenoud L; Roux-Lombard P; De Groote D; Legendre C; Dayer JM; Descamps-Latscha B; Kreis H; Bach JF
    Transplantation; 1995 May; 59(10):1470-5. PubMed ID: 7770936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
    Woodle ES; Bruce DS; Josephson M; Cronin D; Newell KA; Millis JM; Piper JB; O'Laughlin R; Thistlethwaite JR
    Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OKT3 first-dose reaction: association with T cell subsets and cytokine release.
    Gaston RS; Deierhoi MH; Patterson T; Prasthofer E; Julian BA; Barber WH; Laskow DA; Diethelm AG; Curtis JJ
    Kidney Int; 1991 Jan; 39(1):141-8. PubMed ID: 1900552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of indomethacin on the febrile response following OKT3 therapy.
    First MR; Schroeder TJ; Hariharan S; Alexander JW; Weiskittel P
    Transplantation; 1992 Jan; 53(1):91-4. PubMed ID: 1733091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of oral pentoxyfylline on the OKT3-induced cytokine-release syndrome among renal allograft recipients.
    Vasquez EM; Pollak R
    Clin Transplant; 1996 Jun; 10(3):294-7. PubMed ID: 8826669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study.
    Segovia J; Rodríguez-Lambert JL; Crespo-Leiro MG; Almenar L; Roig E; Gómez-Sánchez MA; Lage E; Manito N; Alonso-Pulpón L
    Transplantation; 2006 Jun; 81(11):1542-8. PubMed ID: 16770243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increase of sTNF receptor levels in acute renal allograft rejection after treatment with OKT3.
    Bemelman FJ; Jansen J; van der Poll T; van Deventer SJ; ten Berge RJ
    Nephrol Dial Transplant; 1994; 9(12):1786-90. PubMed ID: 7708265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nosocomial aseptic meningitis associated with administration of OKT3.
    Martin MA; Massanari RM; Nghiem DD; Smith JL; Corry RJ
    JAMA; 1988 Apr; 259(13):2002-5. PubMed ID: 3126308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OKT3 prophylaxis versus conventional drug therapy: single-center perspective, part of a multicenter trial.
    Kahana L; Narvarte J; Ackermann J; LeFor W; Weinstein S; Wright C; deQuesada A; Baxter J; Shires D
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):5-9. PubMed ID: 2510510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pentoxifylline does not prevent the cytokine-induced first dose reaction following OKT3--a randomized, double-blind placebo-controlled study.
    Vincenti F; Danovitch GM; Neylan JF; Steiner RW; Everson MP; Gaston RS
    Transplantation; 1996 Feb; 61(4):573-7. PubMed ID: 8610383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective analysis of the effect of indomethacin on adverse reactions to orthoclone OKT3 in the therapy of acute renal allograft rejection.
    Gaughan WJ; Francos BB; Dunn SR; Francos GC; Burke JF
    Am J Kidney Dis; 1994 Sep; 24(3):486-90. PubMed ID: 8079974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with diminished release of pro-inflammatory cytokines.
    Abbs IC; Clark M; Waldmann H; Chatenoud L; Koffman CG; Sacks SH
    Ther Immunol; 1994 Dec; 1(6):325-31. PubMed ID: 7584508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients.
    Schroeder TJ; First MR; Mansour ME; Alexander JW; Penn I
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):14-8. PubMed ID: 2510506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.